Bluejay Diagnostics Inc. (BJDX)
3.40
-0.25 (-6.85%)
At close: Jan 14, 2025, 3:59 PM
3.44
1.18%
After-hours Jan 14, 2025, 07:38 PM EST
undefined% (undefined)
| Bid | 3.3 |
| Market Cap | 1.88M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -804 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 4.05 |
| Volume | 75,454 |
| Avg. Volume (20D) | 690,104 |
| Open | 3.53 |
| Previous Close | 3.65 |
| Day's Range | 3.30 - 3.60 |
| 52-Week Range | 3.03 - 419.60 |
| Beta | undefined |
About BJDX
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reag...
Industry Medical - Devices
Sector Healthcare
IPO Date Nov 10, 2021
Employees 10
Stock Exchange NASDAQ
Ticker Symbol BJDX
Website https://www.bluejaydx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BJDX stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
1 month ago ·
Source
+59.38%
Bluejay Diagnostics shares are trading higher afte...
Unlock content with
Pro Subscription
2 months ago ·
Source
-28.85%
Bluejay Diagnostics shares are trading lower after the company announced a 1-for-50 reverse stock split.
